Merck & Co., Inc.

Merck (ticker: MRK, currency: USD) still has a powerful economic engine, but it is becoming more concentrated rather than more diversified. The business makes money by discovering, patenting, manufacturing, and selling high-value prescription drugs and vaccines; during exclusivity, pricing power is strong, and once products scale, margins are excellent. Animal Health adds a steadier, less patent-sensitive cash flow stream.

What matters is not whether Merck is profitable today; it obviously is. The real question is whether the engine is broadening. On that measure, the answer is mixed. Keytruda alone was 31680 of 65011 in 2025 sales — nearly half the company. That is extraordinary strength today, but it also means Merck’s economics are increasingly tied to one franchise. Newer products like Winrevair, Capvaxive, Welireg, and Prevymis are helping, and Animal Health is strengthening, but they are not yet large enough to fully de-risk the model.

This is mostly a win-win business: patients get meaningful therapies, health systems often get survival or prevention benefits, and Merck earns high returns when innovation works. The tension is that pharma economics are partly built on patent-protected pricing, so payers will push back hard when differentiation narrows.

The deterioration signs are real: Gardasil fell sharply in 2025, Januvia remains in decline, and Merck’s non-Keytruda growth is much less impressive than the headline suggests. The few numbers that best tell you whether Merck is winning are: Keytruda sales concentration, ex-Keytruda pharmaceutical growth, new-launch revenue scale, Gardasil stabilization, and Animal Health growth.

Conclusion: Merck sells into large, structurally growing healthcare markets, so the market is a tailwind; the catch is that the most valuable part of that market is brutally competitive and Merck’s exposure is increasingly concentrated in one franchise. Using filings through June 30, 2026, the company is still riding favorable demand in oncology, vaccines, and animal health, but the industry profit pool is shifting toward novel biologics where pricing scrutiny, pipeline arms races, and patent cliffs matter more than raw market growth.

Overall, this is a good market, not an easy one: big, growing, and science-driven, but returns are concentrated in a few winning molecules.

Merck has a real moat, but it is narrowing, not widening. The durable part is not “brand”; it is Merck’s ability to discover, run, manufacture, and globalize complex drugs and vaccines through regulatory barriers and scale. The weaker part is that too much of the moat now sits inside Keytruda, which is extraordinary but patent-bound.

As of FY2025, Keytruda was $31.7 billion of sales on $65.0 billion total company revenue, while Gardasil fell to $5.2 billion from $8.9 billion in 2023. That is the core issue: Merck’s platform moat is real, but product concentration is rising. So this is a strong but less diversified moat, with erosion risk driven more by patent concentration than by competitive incompetence.

Conclusion: Merck’s finances are strong enough to absorb normal shocks, but the quality is less pristine than the income statement suggests because capital returns are increasingly concentrated in Keytruda and the balance sheet carries meaningful acquisition baggage.

ROE is high, but it is flattered by buybacks and an intangible-heavy balance sheet; the more important point is that ROIC still appears comfortably above cost of capital, though probably below the very best large-cap pharma peers once you haircut for deal spending. Debt looks prudent rather than desperate: Merck had sizable cash, staggered maturities, and a business that still throws off large operating cash flow, so a normal patent or pricing setback should not threaten solvency.

The weaker spot is cash conversion. In the latest interim filing available, operating cash flow lagged net income materially because working capital absorbed cash, so reported earnings are real but not perfectly clean on a quarter-to-quarter basis. The bigger long-term watch item is the asset mix: goodwill plus intangibles are large, which raises impairment risk if pipeline deals under-earn. I do not see obvious auditor, fraud, or survival-risk red flags.

Merck’s reinvestment runway is adequate but not long at high returns. It still has places to put capital—Keytruda lifecycle management, Winrevair, Capvaxive, animal health, and external pipeline deals—but the bar is now much harder because FY2025 sales reached 65011000000, with 31680000000 from Keytruda alone. That means new capital is increasingly being used to replace a maturing mega-franchise, not extend an underpenetrated one.

Implied organic growth is probably low-single-digit without major pipeline wins. Merck can keep growing, but matching historical ROIC looks unlikely: the easiest, highest-return reinvestment years were the Keytruda build-out years. Recent M&A has been strategically rational, yet more defensive than compounding-oriented.

Return on incremental invested capital still looks positive but lower than legacy franchise returns—best framed as mid-single-digit to low-teens rather than elite pharma economics.

Merck is still a top-tier pharma franchise, but against the best peers it looks more concentrated and less well-insulated from its main patent cliff. Using FY2025 annual data, Merck competes domestically with Bristol Myers Squibb, Pfizer, and Eli Lilly, and globally with AstraZeneca, Roche, and Novartis. The real battleground is oncology scale, pipeline depth, and post-LOE durability. Merck wins on PD-1 breadth: Keytruda reached $31,680,000,000 in 2025, nearly half of company sales, which is both its edge and its vulnerability.

Merck is likely still taking share in oncology through label expansion and newer launches like Winrevair, but at the enterprise level it is not clearly pulling away. Outlook: solid near-term, harder post-Keytruda unless the next wave scales fast.

Conclusion: Merck’s management looks broadly aligned with shareholders, but this is alignment by governance and cash return policy, not by large insider ownership. Using the latest reviewed filing set (FY2025 10-K; Q1 2025 10-Q), the company still looks like a conventional, shareholder-respectful big pharma: no controlling shareholder, no obvious governance scandal, steady dividends, and ongoing buybacks. The weak point is that insiders do not have founder-level skin in the game, so incentives matter more than ownership.

Management Competence & Ethics

Conclusion: competent and generally trustworthy, but not exceptional capital allocators. As of FY2025, Merck looks like a well-run operator that has executed strongly in oncology and new launches, yet still has not diversified away from Keytruda fast enough. Capital allocation is mostly sensible - heavy R&D, dividends, selective buybacks, and business development - but large pipeline deals have been expensive, so value creation is mixed rather than clearly superior. Management is reasonably transparent: the 2025 filing plainly shows Keytruda at $31.68 billion of $65.01 billion sales and Gardasil falling sharply to $5.23 billion, which is not the behavior of a company hiding its weak spots. I see no fresh restatement, auditor-disagreement, or fraud signal in the latest filing; litigation remains a normal pharma overhang, but nothing disclosed here looks existential to the enterprise.

Conclusion: Merck is not obviously absurdly expensive, but at a $366.7B market cap it is priced as if the Keytruda patent cliff will be managed with only modest long-term earnings damage. That is too optimistic for a business where one drug was ~$31.7B of 2025 sales.

I would value Merck on normalized 2031 earnings power, not trailing P/E. Trailing optics are distorted; the real question is what earnings look like after Keytruda exclusivity weakens. My base case assumes Merck roughly offsets part, but not all, of that hole with Winrevair, Capvaxive, Welireg, animal health, and pipeline launches. That gets to roughly $16B net income in 2031; at 18x earnings, intrinsic equity value is about $290B.

Management’s near-term guidance style has historically been reasonably credible on cost control and launch execution, but it has not removed the structural issue: Merck still needs a lot of pipeline and business-development success to replace a mega-blockbuster. I trust 1-2 year guidance far more than any implied 5-year bridge over the 2028-2031 period.

At today’s price, the market is embedding something like high-single-digit earnings growth through the cliff and a still-premium multiple after it. That is possible, but not conservative.

Liquidation value is poor support. Reported equity was $52.6B at 2025 year-end, but hard-asset liquidation would be far lower after $49.3B of debt; most real value sits in patents, brands, and manufacturing know-how. On a rough SOTP basis, Animal Health may be worth $40B-$50B alone, implying the market is valuing the pharma business at $320B+ despite extreme Keytruda concentration.

Conclusion: Merck looks more like a solid capital preserver than a likely multi-bagger from here. Using FY2025 official results, the moat is still real - oncology scale, global commercial reach, manufacturing, regulatory execution, and animal health all matter - but the compounding engine is now too dependent on one product.

Keytruda was USD 31680000000 of USD 65011000000 sales in 2025, or roughly half the company. That concentration is what erodes first. If Merck executes, the stock can still be a 1.5-2.0x in 10 years type outcome through cash generation, dividends, and a successful handoff to newer assets like Winrevair plus the broader oncology pipeline. If it does not, the post-Keytruda period will look much more like value preservation than compounding.

The core issue is incremental capital returns. Merck can still fund R&D and deals at scale, but replacing a drug this large is far harder than extending it. Reinvestment probably sustains relevance, not necessarily superior returns.

Even under adverse conditions, Merck should still be competitively relevant in 10-20 years; it is unlikely to become obsolete. The thesis breaks if ex-Keytruda pharma revenue stops growing while late-stage launches fail to reach scale before Keytruda exclusivity erosion becomes visible.

Conclusion: Merck’s risk profile is dominated by one issue — extreme dependence on Keytruda ahead of patent expiry — while balance-sheet and governance risk remain manageable. As of the most recent filed data I’m using (FY2025 10-K; Q1 2025 10-Q), this is a good business with a real concentration problem, not a fragile one.

The single risk that could permanently impair the business is failing to rebuild earnings power before/after Keytruda exclusivity rolls off. Probability: medium, because the cliff is certain; only the replacement success is uncertain.

Final Verdict: TRACK

Merck is a good large-cap pharma business but not a compelling long-term buy at today's price. The core issue is simple: too much of the franchise’s current earning power sits on Keytruda, and the market is still valuing the company as if that profit pool will be replaced with limited friction. That is not impossible, but it is not the prudent base case.

This is not a bad business. Merck still has real strengths: scale, regulatory know-how, a strong oncology position, animal health, solid cash generation, and credible management. Permanent impairment risk to the business is moderate, not extreme. But for equity holders, the risk is that the price already discounts a smoother post-Keytruda transition than the evidence supports.

The inversion case against a cautious verdict is that management successfully converts today’s cash flows into a broader oncology/immunology portfolio and the patent cliff becomes a manageable plateau rather than a drop. If that happens, today’s forward multiple may look fine. I do not think that outcome is yet proven enough to underwrite aggressively.

So the right action is TRACK, not BUY. For new money, wait for either a better price or stronger evidence that the replacement pipeline can offset Keytruda concentration. For existing holders, TRIM is reasonable if the position is large; otherwise hold only if you are explicitly comfortable with the patent-cliff bet.

If you own it: not a panic sell, but this is not a “buy more aggressively” setup.

What to research further before acting

• Phase 3 depth and timing of the post-Keytruda pipeline
• Durability of Gardasil, Winrevair, and animal health growth
• Acquisition ROI versus internal R&D productivity
• Post-LOE earnings power under conservative pricing and margin assumptions